Although the recently concluded CLEOPATRA trial showed clinical benefits of combining
trastuzumab and pertuzumab for treating HER2-positive metastatic breast cancer …

Since their discovery by Bangham about 50 years ago, liposomes have become promising
tools in drug delivery systems. This has increased the therapeutic index of many drugs, and …

Biologics are increasingly becoming part of routine disease management. As more agents
are developed, the challenge of keeping track of indications and side effects is growing …

Human T lymphocytes can be redirected with a new defined specificity by expression of a
chimeric T-cell receptor (immunoreceptor) for the use in adoptive immunotherapy of cancer …

Antibodies to the extracellular region of the ErbB receptors have played key roles in the
development of a mechanistic understanding of this family of receptor tyrosine kinases. An …

HER2 positive JIMT-1 breast tumors are resistant to trastuzumab treatment in vitro and
develop resistance to trastuzumab in vivo in SCID mice. We explored whether these …

Amplification of the HER2 gene and/or overexpression of its protein product have been
found in up to 25% to 30% of human breast cancers and have been shown to be associated …

Introduction Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR.
Based on phase I data, the recommended dose has been established at 200 mg weekly …

In vivo imaging of human epidermal growth factor receptor type 2 (HER2) expression may
allow direct assessment of HER2 status in tumor tissue and provide a means to quantify …

Uterine papillary serous carcinoma (UPSC) is a rare and aggressive variant of endometrial
carcinoma. Little is known about the pathological and biological features of this tumor …